Navigation Links
New Cancer Treatment Stops Aggressive Sarcomas
Date:2/24/2009

NASHVILLE, Tenn., Feb. 25 /PRNewswire/ -- After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.

One of the patients is an 18-year-old with malignant fibrous histiocytoma (MFH) that arose in the largest bone of his leg. The cancer spread throughout his lungs, despite aggressive surgery that replaced most of his leg with metal implants. The second patient was losing a battle with desmoplastic small round cell tumor (DSRCT), a very rare and aggressive cancer. After undergoing multiple surgical procedures and different chemotherapy regimens, the DSRCT still progressed and spread through the abdomen.

After eight weeks of the NeoPlas regimen, scans showed that both patients' cancers had stopped their growth, and some tumors actually had regressed. Additionally, both patients are tolerating the treatment well and are able to carry on normal activities. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are early results and not statistically valid yet. Still, the sarcomas as a group are so aggressive and uniformly fatal that being able to stop their growth and spread is very exciting. It's a major victory for these individuals, and it mirrors the success we're seeing in the great majority of patients so far." The protocol also is offered for qualifying patients with mesothelioma, colon cancer, renal (kidney) cancer, pancreatic cancer and melanoma.

This investigative treatment is a combination of lovastatin, typically used as a cholesterol lowering agent, and interferon. According to Dr. Cantrell, "The key to success has been starting with a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, tumors have begun regressing, sometimes within just a few weeks."

Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

A web site, www.neoplas.org, provides answers to common questions and a screening tool. Individuals can reach NeoPlas Innovation at 615-371-8100.

    EDITORS' NOTE: For an interview with Dr. Cantrell, call 615-371-8100.

'/>"/>
SOURCE NeoPlas Innovation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
2. Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
3. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
4. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
5. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
6. Researchers Discover Metabolite Linked to Aggressive Prostate Cancer
7. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
8. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
9. deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
10. Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
11. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy ... KlipPro KP-240L clipper is available to the public. This is an unusual clipper because ... than the average clipper. , Everything about this product is concentrated on ease of ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be ... a preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... quickly and easily add stylish color grades to their footage. A LUT is a ...
(Date:5/28/2016)... ... ... the city where’s it’s easy to spot the neon lights of chains serving fast food, ... with a taste for real food. , On May 13, the Best Western ... casual restaurant focusing on dishes made by hand with wholesome, organic ingredients that are sourced ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue ... Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in ... Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
Breaking Medicine News(10 mins):